Business
KALY - Kali-Extracts Announces 25 mg CBD Extract Formulation For $600 Million Cannabis Beverage Market
KALY - Kali-Extracts Announces 25 mg CBD Extract Formulation For $600 Million Cannabis Beverage Market.
About this update from Nouveau Life Pharmaceuticals, Inc.
[{"type":"text","content":"\nDALLAS, March 29, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced finalizing it’s all new 25 mg CBD Extract formulation for beverage infusion.  KALY’s patented extraction process already produces a 10 mg CBD formulation for Puration, Inc.’s (USOTC: PURA) (“PURA”) leading EVERx CBD Sports Water.  Few CBD beverages today even have 5 mg of CBD and now KALY will supply a 25 mg formulation.  Management thoroughly evaluated the 25 mg CBD formulation for infusion into a drink that is clear looking and tasting in a suspension with an effective retail shelf-life.  KALY indicates its formulation will be on shelves infused into its first beverage within the next 30 days.\n KALY earlier this week announced that the State of Texas plans to remove hemp as a controlled substance next week in conjunction with the United States 2018 Farm Act is just the type of market condition management is looking for to support the implantation of the previously announced cannabis extraction lab to be dedicated to the 100 acre hemp farm to be operated by partner Nouveau (USOTC: NOUV).  KALY and NOUV plan to partner on the development of a proprietary hemp cultivar dedicated to the advancement of KALY’s pharmaceutical extract developments.  The continuing liberalization of cannabis laws, such as the hemp removal as a controlled substance in Texas, supports the work KALY is advancing. Last week, KALY published a research report on the recent pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates using an extract derived from KALY’s patented cannabis extraction process.  The report details the study method and the significance of the study.  The report includes specific findings and due to the substantial findings, the report includes guidelines for next stage tests. The full report can be read on the company’s website at www.kali-extracts.com. Goldman Small Cap Research Report has published an analyst research report on KALY that highlights KALY’s cannabis pharmaceutical value.  The report is available under “research” on the OTCMarkets website. The research report is the first report from Goldman Small Cap Research as par...